Braveheart Bio

Biotech · Public

Cardiac myosin inhibitor molecule for heart disease treatment

braveheart.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2015OSTREA BIO, INC.——
2016Crystalys——
2017Homology Medicines—$107M
2018Braveheart Bio——
2019Outer Biosciences, LLC—$4.0M
2020VITAKEY, INC.—$44M
2021SOMATOCEUTICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.